BioLineRx Statistics
Total Valuation
BioLineRx has a market cap or net worth of $14.72 million. The enterprise value is $10.15 million.
Important Dates
The last earnings date was Wednesday, May 27, 2026, before market open.
| Earnings Date | May 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BioLineRx has 2.66 billion shares outstanding. The number of shares has increased by 73.94% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 2.66B |
| Shares Change (YoY) | +73.94% |
| Shares Change (QoQ) | -0.08% |
| Owned by Insiders (%) | 0.39% |
| Owned by Institutions (%) | 3.31% |
| Float | 2.51B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 10.50 |
| Forward PS | 10.01 |
| PB Ratio | 0.71 |
| P/TBV Ratio | 45.29 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 7.24 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.58, with a Debt / Equity ratio of 0.44.
| Current Ratio | 1.58 |
| Quick Ratio | 1.41 |
| Debt / Equity | 0.44 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -10.08 |
Financial Efficiency
Return on equity (ROE) is -46.72% and return on invested capital (ROIC) is -21.12%.
| Return on Equity (ROE) | -46.72% |
| Return on Assets (ROA) | -16.55% |
| Return on Invested Capital (ROIC) | -21.12% |
| Return on Capital Employed (ROCE) | -43.30% |
| Weighted Average Cost of Capital (WACC) | 8.23% |
| Revenue Per Employee | $58,417 |
| Profits Per Employee | -$329,292 |
| Employee Count | 24 |
| Asset Turnover | 0.03 |
| Inventory Turnover | 0.11 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -17.90% in the last 52 weeks. The beta is 0.59, so BioLineRx's price volatility has been lower than the market average.
| Beta (5Y) | 0.59 |
| 52-Week Price Change | -17.90% |
| 50-Day Moving Average | 2.72 |
| 200-Day Moving Average | 3.16 |
| Relative Strength Index (RSI) | 58.23 |
| Average Volume (20 Days) | 111,679 |
Short Selling Information
The latest short interest is 139,481, so 3.21% of the outstanding shares have been sold short.
| Short Interest | 139,481 |
| Short Previous Month | 157,501 |
| Short % of Shares Out | 3.21% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 5.48 |
Income Statement
In the last 12 months, BioLineRx had revenue of $1.40 million and -$7.90 million in losses. Loss per share was -$0.00.
| Revenue | 1.40M |
| Gross Profit | 1.11M |
| Operating Income | -10.90M |
| Pretax Income | -9.74M |
| Net Income | -7.90M |
| EBITDA | -10.75M |
| EBIT | -10.90M |
| Loss Per Share | -$0.00 |
Full Income StatementBalance Sheet
The company has $17.35 million in cash and $9.07 million in debt, with a net cash position of $8.28 million or $0.00 per share.
| Cash & Cash Equivalents | 17.35M |
| Total Debt | 9.07M |
| Net Cash | 8.28M |
| Net Cash Per Share | $0.00 |
| Equity (Book Value) | 20.84M |
| Book Value Per Share | 0.01 |
| Working Capital | 7.96M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$7.76 million and capital expenditures -$31,000, giving a free cash flow of -$7.79 million.
| Operating Cash Flow | -7.76M |
| Capital Expenditures | -31,000 |
| Depreciation & Amortization | 150,000 |
| Net Borrowing | -4.94M |
| Free Cash Flow | -7.79M |
| FCF Per Share | -$0.00 |
Full Cash Flow StatementMargins
| Gross Margin | 79.24% |
| Operating Margin | -777.46% |
| Pretax Margin | -694.79% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BioLineRx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -73.94% |
| Shareholder Yield | -73.94% |
| Earnings Yield | -53.69% |
| FCF Yield | -52.95% |
Analyst Forecast
The average price target for BioLineRx is $17.50, which is 423.95% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $17.50 |
| Price Target Difference | 423.95% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (3Y) | 70.05% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 30, 2025. It was a reverse split with a ratio of 1:40.
| Last Split Date | Jan 30, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:40 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |
